Icatibant Zentiva (Icatibant Acetate)

Icatibant acetate acts as a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema.

The dosing regimen for Icatibant Zentiva is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidance. Only a qualified prescriber should set the dose and frequency of administration.

Safety data for icatibant acetate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the Icatibant Zentiva product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

The primary alternative for HAE is plasma‑derived or recombinant C1‑esterase inhibitor replacement therapy. While C1‑INH restores deficient protein activity, icatibant directly blocks the bradykinin B2 receptor, offering a rapid, subcutaneous option that does not require intravenous infusion. Choice of therapy depends on patient preference, attack severity and clinical guidelines.

Icatibant Zentiva must be stored refrigerated at 2 °C to 8 °C. The product should be kept in its original packaging, protected from light, and must not be frozen or shaken. If refrigeration is temporarily unavailable, the product may be kept at controlled room temperature for a limited period as indicated in the labeling.

Icatibant Zentiva is supplied as a sterile injection solution for subcutaneous injection. The dose is typically administered by the patient or a caregiver into the abdominal wall or thigh using a pre‑filled syringe or autoinjector, following the instructions provided by the prescribing clinician.

Serious adverse reactions include anaphylaxis, severe hypotension, and angioedema that may involve the airway. These events require immediate medical attention. Patients should be educated to recognize early signs of these reactions and seek emergency care promptly if they occur.

Icatibant Zentiva is contraindicated in individuals with known hypersensitivity to icatibant acetate or any component of the formulation. Caution is also advised for patients with severe cardiovascular disease, uncontrolled hypertension, or those who are pregnant or breastfeeding unless the potential benefit outweighs the risk.